Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Two-stage Vectors Deliver Gene Silencing Therapy to Tumors

Abstract:
Breast cancer patients with the so-called triple negative form of the disease have the lowest survival rate among all breast cancer patients, in large part because this type of cancer does not respond to most anti-cancer agents. Recent studies have shown, though, that triple negative breast cancers are susceptible to agents that interfere with DNA repair pathways, especially a protein known as ATM. Now, a research team from The Methodist Hospital Research has capitalized on this weakness with promising results.

Two-stage Vectors Deliver Gene Silencing Therapy to Tumors

Bethesda, MD | Posted on March 7th, 2013

Haifa Shen and Mauro Ferrari led a team of investigators that created a two-stage delivery vehicle capable of ferrying an agent that targets this protein to triple negative breast tumors. When administered to mice bearing human breast tumors, the drug-bearing vector stopped the production of the ATM protein and greatly inhibited the growth of what otherwise is an aggressive cancer. The researchers published the results of their work in the journal Small. Dr. Ferrari is co-principal investigator of the Texas Center for Cancer Nanomedicine, one of nine Centers of Cancer Nanotechnology Excellence funded by the National Cancer Institute.

To stop the production of ATM, the researchers created a short interfering RNA (siRNA) that targets the messenger RNA that codes for this protein. siRNA-based therapies have shown promise for treating cancer, but delivering them to tumors at therapeutic levels has proven challenging. Dr. Shen and Dr. Ferrari solved this problem using a two-stage delivery vehicle consisting of a nanoscale liposome and a disc-shaped, nanoporous silicon microparticle. The researchers use the liposome to encapsulate the siRNA agent and they take advantage of the biocompatible silicon microparticles to safely ferry the liposomes through the blood stream and deposit them just outside of the tumors.

Because of their disc shape, the silicon microparticles accumulate efficiently in the blood vessels that surround tumors. In earlier work, Dr. Ferrari and his Texas Center for Cancer Nanomedicine colleague Paulo Decuzzi had shown that approximately between six and 10 percent of an injected dose of silicon microparticles accumulate in the tumor vasculature compared to less than 0.1 percent of conventionally administered drug. Once the microparticles settle around the tumor, they gradually degrade into non-toxic materials and slowly release the liposomes. The liposomes then migrate into the tumors, where they are taken up by cancer cells and release their siRNA payload.

While experiments in tumor bearing mice showed that this two-stage delivery system was effective at suppressing tumor growth, they also demonstrated that it did not trigger a potentially dangerous immune response that is often seen with siRNA therapies. Additionally, during the four-week experiments, body weight, blood chemistry, and tissue histology did not reveal significant toxicities which are often associated with chemotherapies.

####

About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

Copyright © The National Cancer Institute (NCI)

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

View abstract - "Multistage Vectored siRNA Targeting Ataxia-Telangiectasia Mutated for Breast Cancer Therapy."

Related News Press

News and information

CubeSat Structures Competition Opens Space Design to Students of the World December 16th, 2017

Record high photoconductivity for new metal-organic framework material December 15th, 2017

Error-free into the quantum computer age December 15th, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Govt.-Legislation/Regulation/Funding/Policy

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Nanomedicine

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Discoveries

Quantum memory with record-breaking capacity based on laser-cooled atoms December 15th, 2017

Record high photoconductivity for new metal-organic framework material December 15th, 2017

Error-free into the quantum computer age December 15th, 2017

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

Announcements

CubeSat Structures Competition Opens Space Design to Students of the World December 16th, 2017

Record high photoconductivity for new metal-organic framework material December 15th, 2017

Error-free into the quantum computer age December 15th, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project